ASCLS eNewsBytes

• Rocket's Therapy for Rare Immunodeficiency Gets Accelerated FDA Approval April 7, 2026
  Rocket Pharmaceuticals has received accelerated FDA approval for Kresladi, a gene therapy derived from autologous hematopoietic stem cells, designed to treat severe leukocyte adhesion deficiency-I in children.
• New AI Test Estimates Individualized Chemotherapy Benefit in Breast Cancer Patients April 7, 2026
  Ataraxis AI has introduced Ataraxis Breast CTX, a predictive AI test that estimates personalized chemotherapy benefits for breast cancer patients. This innovative tool is the first to provide patient-specific predictions for adjuvant chemotherapy benefit, contrasting with traditional genomic assays that rely on population-level data for recurrence risk assessment.
• Most Common Bacterial Coinfections Identified in Children With RSV April 7, 2026
  Researchers identified common bacterial pathogens, including Streptococcus pneumoniae and Haemophilus influenzae, co-detected in children with RSV infection. A review emphasizes strategies for early diagnosis, rational antibiotic use to combat antimicrobial resistance and future therapeutic development.
• COVID-19 and POTS: Is There a Link? April 7, 2026
  Many recover from COVID-19 within weeks, but some have prolonged symptoms. Researchers are investigating this phenomenon, and those with "long-haul COVID" may be developing postural orthostatic tachycardia syndrome.
• FDA Approves Dermal Filler for Temple Hollowing Indication April 7, 2026
  Restylane Contour, a hyaluronic acid injectable filler, has been FDA approved for correcting temple hollowing in patients over 21. This approval broadens its application beyond prior uses for cheek augmentation and midface contour loss.